Literature DB >> 15531498

Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes.

Sandeep Dhindsa1, Sathyavani Prabhakar, Manak Sethi, Arindam Bandyopadhyay, Ajay Chaudhuri, Paresh Dandona.   

Abstract

Type 2 diabetes is associated with lower total testosterone (T) levels in cross-sectional studies. However, it is not known whether the defect is primary or secondary. We investigated the prevalence of hypogonadism in type 2 diabetes by measuring serum total T, free T (FT), SHBG, LH, FSH, and prolactin (PRL) in 103 type 2 diabetes patients. FT was measured by equilibrium dialysis. FT was also calculated by using T and SHBG (cFT). Hypogonadism was defined as low FT or cFT. The mean age was 54.7 +/- 1.1 yr, mean body mass index (BMI) was 33.4 +/- 0.8 kg/m(2), and mean HbA1c was 8.4 +/- 0.2%. The mean T was 12.19 +/- 0.50 nmol/liter (351.7 +/- 14.4 ng/dl), SHBG was 27.89 +/- 1.65 nmol/liter, and FT was 0.250 +/- 0.014 nmol/liter. Thirty-three percent of patients were hypogonadal. LH and FSH levels were significantly lower in the hypogonadal group compared with patients with normal FT levels (3.15 +/- 0.26 vs. 3.91 +/- 0.24 mIU/ml for LH and 4.25 +/- 0.45 vs. 5.53 +/- 0.40 mIU/ml for FSH; P < 0.05). There was a significant inverse correlation of BMI with FT (r = -0.382; P < 0.01) and T (r = -0.327; P < 0.01). SHBG correlated inversely with BMI (r = -0.267; P < 0.05) but positively with age (r = 0.538; P < 0.001) and T (r = 0.574; P < 0.001). FT correlated strongly with cFT (r = 0.919; P < 0.001) but not with SHBG. LH levels correlated positively with FT (r = 0.287; P < 0.05). We conclude that hypogonadotropic hypogonadism occurs commonly in type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15531498     DOI: 10.1210/jc.2004-0804

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  126 in total

Review 1.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

2.  Combined inhibition of aromatase activity and dihydrotestosterone supplementation attenuates renal injury in male streptozotocin (STZ)-induced diabetic rats.

Authors:  Michaele B Manigrasso; R Taylor Sawyer; Zachary M Hutchens; Elizabeth R Flynn; Christine Maric-Bilkan
Journal:  Am J Physiol Renal Physiol       Date:  2012-02-01

3.  Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty.

Authors:  Anne M Kenny; Alison Kleppinger; Kristen Annis; Margaret Rathier; Bruce Browner; James O Judge; Daniel McGee
Journal:  J Am Geriatr Soc       Date:  2010-06       Impact factor: 5.562

4.  Effect of Testosterone on FGF2, MRF4, and Myostatin in Hypogonadotropic Hypogonadism: Relevance to Muscle Growth.

Authors:  Husam Ghanim; Sandeep Dhindsa; Manav Batra; Kelly Green; Sanaa Abuaysheh; Nitesh D Kuhadiya; Antoine Makdissi; Ajay Chaudhuri; Paresh Dandona
Journal:  J Clin Endocrinol Metab       Date:  2019-06-01       Impact factor: 5.958

5.  Stem cell treatment for complicated diabetes.

Authors:  Jong Yoon Bahk; Hoon Han; Youn Soo Lee
Journal:  Int J Stem Cells       Date:  2008-11       Impact factor: 2.500

Review 6.  Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels.

Authors:  Ronald S Swerdloff; Robert E Dudley; Stephanie T Page; Christina Wang; Wael A Salameh
Journal:  Endocr Rev       Date:  2017-06-01       Impact factor: 19.871

7.  Insulin directly regulates steroidogenesis via induction of the orphan nuclear receptor DAX-1 in testicular Leydig cells.

Authors:  Seung Won Ahn; Gil-Tae Gang; Yong Deuk Kim; Ryun-Sup Ahn; Robert A Harris; Chul-Ho Lee; Hueng-Sik Choi
Journal:  J Biol Chem       Date:  2013-04-15       Impact factor: 5.157

Review 8.  Endocrine causes of nonalcoholic fatty liver disease.

Authors:  Laura Marino; François R Jornayvaz
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

9.  Testosterone concentrations in diabetic and nondiabetic obese men.

Authors:  Sandeep Dhindsa; Michael G Miller; Cecilia L McWhirter; Donald E Mager; Husam Ghanim; Ajay Chaudhuri; Paresh Dandona
Journal:  Diabetes Care       Date:  2010-03-03       Impact factor: 19.112

Review 10.  The many faces of testosterone.

Authors:  Jerald Bain
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.